Adoptive cell therapy (ACT) with antigen-specific T cells has shown remarkable clinical success; however, approaches to safely and effectively augment T cell function, especially in solid tumors, remain of great interest. Here we describe a strategy to 'backpack' large quantities of supporting protein drugs on T cells by using protein nanogels (NGs) that selectively release these cargos in response to T cell receptor activation. We designed cell surface–conjugated NGs that responded to an increase in T cell surface reduction potential after antigen recognition and limited drug release to sites of antigen encounter, such as the tumor microenvironment. By using NGs that carried an interleukin-15 super-agonist complex, we demonstrated that, relative to systemic administration of free cytokines, NG delivery selectively expanded T cells 16-fold in tumors and allowed at least eightfold higher doses of cytokine to be administered without toxicity. The improved therapeutic window enabled substantially increased tumor clearance by mouse T cell and human chimeric antigen receptor (CAR)-T cell therapy in vivo.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Biomarker Research Open Access 01 December 2023
Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy
Nature Communications Open Access 24 October 2023
Signal Transduction and Targeted Therapy Open Access 07 August 2023
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Rosenberg, S.A. & Restifo, N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
Gill, S. & June, C.H. Going viral: chimeric antigen receptor T cell therapy for hematological malignancies. Immunol. Rev. 263, 68–89 (2015).
Corrigan-Curay, J. et al. T cell immunotherapy: looking forward. Mol. Ther. 22, 1564–1574 (2014).
Johnson, L.A. et al. Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med. 7, 275ra22 (2015).
Klebanoff, C.A. et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA 101, 1969–1974 (2004).
Wallace, A. et al. Transforming growth factor–β receptor blockade augments the effectiveness of adoptive T cell therapy of established solid cancers. Clin. Cancer Res. 14, 3966–3974 (2008).
Conlon, K.C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74–82 (2015).
Leonard, J.P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 90, 2541–2548 (1997).
Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278–2288 (2015).
Huang, B. et al. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci. Transl. Med. 7, 291ra94 (2015).
Stephan, M.T., Moon, J.J., Um, S.H., Bershteyn, A. & Irvine, D.J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16, 1035–1041 (2010).
Stephan, M.T., Stephan, S.B., Bak, P., Chen, J. & Irvine, D.J. Synapse-directed delivery of immunomodulators using T cell–conjugated nanoparticles. Biomaterials 33, 5776–5787 (2012).
Ghezzi, P., Bonetto, V. & Fratelli, M. Thiol-disulfide balance: from the concept of oxidative stress to that of redox regulation. Antioxid. Redox Signal. 7, 964–972 (2005).
Lawrence, D.A., Song, R. & Weber, P. Surface thiols of human lymphocytes and their changes after in vitro and in vivo activation. J. Leukoc. Biol. 60, 611–618 (1996).
Berridge, M.V. & Tan, A.S. Trans-plasma membrane electron transport: a cellular assay for NADH- and NADPH-oxidase based on extracellular, superoxide-mediated reduction of the sulfonated tetrazolium salt WST-1. Protoplasma 205, 74–82 (1998).
Berridge, M.V. & Tan, A.S. Cell-surface NAD(P)H-oxidase: relationship to trans-plasma membrane NADH-oxidoreductase and a potential source of circulating NADH-oxidase. Antioxid. Redox Signal. 2, 277–288 (2000).
Riber, C.F., Smith, A.A. & Zelikin, A.N. Self-immolative linkers literally bridge disulfide chemistry and the realm of thiol-free drugs. Adv. Healthc. Mater. 4, 1887–1890 (2015).
Jones, L.R. et al. Releasable luciferin–transporter conjugates: tools for the real-time analysis of cellular uptake and release. J. Am. Chem. Soc. 128, 6526–6527 (2006).
Xu, J. et al. Rendering protein-based particles transiently insoluble for therapeutic applications. J. Am. Chem. Soc. 134, 8774–8777 (2012).
Zhu, X. et al. Novel human interleukin-15 agonists. J. Immunol. 183, 3598–3607 (2009).
Rhode, P.R. et al. Comparison of the superagonist complex, ALT-803, to IL-15 as cancer immunotherapeutics in animal models. Cancer Immunol. Res. 4, 49–60 (2016).
Yu, A., Olosz, F., Choi, C.Y. & Malek, T.R. Efficient internalization of IL-2 depends on the distal portion of the cytoplasmic tail of the IL-2R common γ-chain and a lymphoid cell environment. J. Immunol. 165, 2556–2562 (2000).
Overwijk, W.W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569–580 (2003).
Maude, S.L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
Maus, M.V. et al. Adoptive immunotherapy for cancer or viruses. Annu. Rev. Immunol. 32, 189–225 (2014).
Guo, Y. et al. IL-15 superagonist-mediated immunotoxicity: role of NK cells and IFN-γ. J. Immunol. 195, 2353–2364 (2015).
Patel, S.K., Zhang, Y., Pollock, J.A. & Janjic, J.M. Cyclooxgenase-2 inhibiting perfluoropoly (ethylene glycol) ether theranostic nanoemulsions–in vitro study. PLoS One 8, e55802 (2013).
Pradhan, D. & Morrow, J. The spectrin–ankyrin skeleton controls CD45 surface display and interleukin-2 production. Immunity 17, 303–315 (2002).
Chang, V.T. et al. Initiation of T cell signaling by CD45 segregation at 'close contacts'. Nat. Immunol. 17, 574–582 (2016).
Johnson, K.G., Bromley, S.K., Dustin, M.L. & Thomas, M.L. A supramolecular basis for CD45 tyrosine phosphatase regulation in sustained T cell activation. Proc. Natl. Acad. Sci. USA 97, 10138–10143 (2000).
Wang, L. et al. Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines. Nanomedicine (Lond.) 10, 473–482 (2014).
Scott, E.A. et al. Protein adsorption and cell adhesion on nanoscale bioactive coatings formed from poly(ethylene glycol) and albumin microgels. Biomaterials 29, 4481–4493 (2008).
Tan, H. et al. PEG-urokinase nanogels with enhanced stability and controllable bioactivity. Soft Matter 8, 2644–2650 (2012).
Lin, X. et al. Oxidative stress in malignant melanoma enhances tumor necrosis factor–α secretion of tumor-associated macrophages that promote cancer cell invasion. Antioxid. Redox Signal. 19, 1337–1355 (2013).
Koshy, S.T., Ferrante, T.C., Lewin, S.A. & Mooney, D.J. Injectable, porous and cell-responsive gelatin cryogels. Biomaterials 35, 2477–2487 (2014).
Singh, N. et al. Bioresponsive mesoporous silica nanoparticles for triggered drug release. J. Am. Chem. Soc. 133, 19582–19585 (2011).
Au, K.M. et al. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: turning a bone anti-resorptive agent into an anticancer therapeutic. Biomaterials 82, 178–193 (2016).
Ling, D. et al. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. ACS Nano 8, 8027–8039 (2014).
Yang, Y. et al. Polymer nanoparticles modified with photo- and pH-dual-responsive polypeptides for enhanced and targeted cancer therapy. Mol. Pharm. 13, 1508–1519 (2016).
Chmielewski, M., Kopecky, C., Hombach, A.A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697–5706 (2011).
Chinnasamy, D. et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor 2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18, 1672–1683 (2012).
Pegram, H.J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133–4141 (2012).
Weinstein-Marom, H. et al. Membrane-attached cytokines expressed by mRNA electroporation act as potent T cell adjuvants. J. Immunother. 39, 60–70 (2016).
Desnoyers, L.R. et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci. Transl. Med. 5, 207ra144 (2013).
Wu, C.-Y., Roybal, K.T., Puchner, E.M., Onuffer, J. & Lim, W.A. Remote control of therapeutic T cells through a small-molecule-gated chimeric receptor. Science 350, aab4077 (2015).
Fedorov, V.D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5, 215ra172 (2013).
Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71–75 (2013).
Morgan, R.A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).
Han, K.P. et al. IL-15:IL-15 receptor–α superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56, 804–810 (2011).
Zheng, Y. et al. In vivo targeting of adoptively transferred T cells with antibody- and cytokine-conjugated liposomes. J. Control. Release 172, 426–435 (2013).
We thank K.D. Wittrup (MIT) for the gift of the engineered IL-2-Fc constructs and the Koch Institute Swanson Biotechnology Center for technical support on flow cytometry, IVIS imaging and MALDI mass spectrometry. This work was supported in part by the Ragon Institute of MGH, MIT and Harvard (D.J.I.), the Melanoma Research Alliance (award 306833; D.J.I.), the NIH (Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute and CA172164; D.J.I.) and the Koch Institute Marble Center for Cancer Nanomedicine (D.J.I.). L.T. was funded by a Cancer Research Institute (CRI) Irvington Postdoctoral Fellowship, and Y.Z. was supported by a National Science fellowship from the Agency for Science, Technology and Research, Singapore. L.T. and Y.-Q.X. were supported by the ISREC Foundation with a donation from the Biltema Foundation and Swiss National Science Foundation (project grant 315230_173243). M.V.M. was supported by NIH grant CA K08166039. D.J.I. is an investigator of the Howard Hughes Medical Institute.
D.J.I., L.T., and Y.Z. are inventors on licensed patents related to the technology described in this manuscript. D.J.I. is a co-founder of Torque Therapeutics, which licensed patents related to this technology.
About this article
Cite this article
Tang, L., Zheng, Y., Melo, M. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol 36, 707–716 (2018). https://doi.org/10.1038/nbt.4181
This article is cited by
Molecular Cancer (2023)
Biomarker Research (2023)
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies
Journal of Hematology & Oncology (2023)
Molecular Cancer (2023)
Nature Nanotechnology (2023)